Genitourinary Radiology: Page 19

Ezra gets FDA clearance for prostate AI software
By AuntMinnie.com staff writers
Cancer screening startup Ezra has received U.S. Food and Drug Administration (FDA) clearance for Ezra Prostate AI, an artificial intelligence (AI)-based software application designed to help radiologists analyze and segment prostate MRI exams.
October 19, 2020
2020 10 20 18 29 1638 2020 10 20 Ezra 3 D Prostate Lesion Ai 20201020184140
PET-based optical imaging detects prostate cancer
By Brian Casey
A PET-based optical imaging technique called Cerenkov luminescence imaging was successfully used by German researchers to confirm the presence of cancer cells after prostate cancer surgery, according to a study published in the October edition of the Journal of Nuclear Medicine.
October 7, 2020
2020 10 08 03 27 8200 2020 10 08 Cerenkov 20201008031426
MRI-guided biopsy improves prostate cancer assessment
By Kate Madden Yee
In-bore MRI-guided biopsy following a positive transrectal ultrasound-guided prostate biopsy finds missed cancers and improves disease assessment, according to a study published September 25 in Radiology: Imaging Cancer.
September 29, 2020
2020 09 29 23 48 1781 2020 09 30 Rad Imaging Cancer Elfatairy Figure2 20200930070149
Race affects access to prostate cancer PET
By Kate Madden Yee
Black men have less access to PET imaging for recurrent prostate cancer with a radiotracer that appears to be more effective than the more commonly used F-18 fluciclovine, according to a study published September 25 in the Journal of Nuclear Medicine.
September 27, 2020
2019 04 17 20 48 2514 Prostate 3 D 400
Telix files NDA for prostate cancer PET imaging agent
By AuntMinnie.com staff writers
Radiopharmaceutical company Telix Pharmaceuticals has submitted a new drug application (NDA) to the U.S. Food and Drug Administration for TLX591-CDx, its gallium-68-based radiopharmaceutical for PET imaging of prostate cancer.
September 23, 2020
2017 06 15 10 31 55 42 Prostate 400
Siemens's AI-based MRI applications get FDA nod
By AuntMinnie.com staff writers
The U.S. Food and Drug Administration (FDA) cleared two new artificial intelligence (AI)-based MRI interpretation applications from Siemens Healthineers.
August 18, 2020
2019 12 03 17 03 9108 Siemens Rsna 2019 400
CEUS helps predict chronic kidney disease progression
By Theresa Pablos
Clinicians may be able to use contrast-enhanced ultrasound (CEUS) features to help predict which patients with chronic kidney disease will experience worse outcomes, according to the findings of a prospective study published on August 9 in Ultrasound in Medicine & Biology.
August 13, 2020
2019 06 18 22 06 2521 Kidneys 400
Follow-up SPECT/CT scan tracks radionuclide dose
By Kate Madden Yee
Australian researchers have developed a technique that uses a follow-up SPECT/CT scan after radionuclide therapy to personalize the radiation dose delivered, according to a study published in the July issue of the Journal of Nuclear Medicine.
August 12, 2020
2020 08 12 22 20 8906 2020 08 13 Snmmi Radiation Dose 20200812222205 20200812222353
GE, Osprey announce distribution deal
By AuntMinnie.com staff writers
GE Healthcare and Osprey Medical have signed a four-year agreement under which GE will distribute Osprey's DyeVert contrast minimization device in Europe, Russia, the Middle East, Africa, Central Asia, and Turkey.
August 5, 2020
2020 01 29 18 12 5932 Ge Rsna 2019 400
SNMMI 2020: AI analysis of PET could help classify prostate cancer
By Erik L. Ridley
An artificial intelligence (AI) algorithm may be able to assist in classifying prostate lesions on 3D prostate-specific membrane antigen-PET exams, according to research presented at the annual meeting of the Society of Nuclear Medicine and Molecular Imaging (SNMMI).
July 16, 2020
2019 04 17 20 48 2514 Prostate 3 D 400
SNMMI 2020: Researchers develop novel prostate cancer agents
By Theresa Pablos
Research on prostate cancer imaging agents that can be produced faster and cheaper than current radiotracers -- and also have therapeutic potential -- was presented by a group from Memorial Sloan Kettering Cancer Center at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2020 virtual annual meeting.
July 16, 2020
2020 07 15 23 29 3710 Cancer Cells Prostate 400
SNMMI 2020: PSMA-PET/CT changes prostate cancer management
By Kate Madden Yee
PET/CT imaging with an F-18 DCFPyL prostate-specific membrane antigen (PSMA) radiopharmaceutical changed prostate cancer management in two-thirds of cases, according to research presented July 13 at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2020 virtual annual meeting.
July 14, 2020
2020 07 14 23 23 6106 2020 07 13 Snmmi Pet Ct Prostate Thumb
Previous Page
Page 19 of 93
Next Page